RE:RE:RE:RE:RE:RE:RE:RE:CR at 450I think they are focused strictly on NMIBC Phase II right now in terms of keeping us up to date and probably because we are so close. Nothing else has been shown to move the stock price and they have shown that they care more about their business/research than the share price so I am sure there is lots going on behind the scenes and we will know in due time.
It's funny how when we don't get regular updates on some things it is taken as a negative and then we wonder why the stock price is where it's at. Seems contradictory to me but I guess the conversations help pass the time.
99942Apophis wrote: fredgoodwinson wrote
Well that would be the Toxicity study for Rutherrin which despite its` clear superiority over TLD-1433 as calibrated and set out by Dr.Lilge in an AGM lecture over 5 years` ago they have progessively rowed back from over the past few years.
They did mention earlier this year that they might commence the Study in Q4 2022 but given the history of delays to date we can`t rely on this as a timeline.
As a pre-requisite for any Clinical Trial with a Rutherrin/ low dose x-ray combinaton and given the astonishing breakthrough that success would represent for patients and medicine alike their seeming indifference to the progress of this their by far most valuable current asset is a complete mystery.
Yes fredgoodwinson curious as to what will unfold and how! Perhaps TLT will reveal a clearer picture after BTD & AA. With a joint venture and a substantial cash flow I would guess multiple attacks at their job jar could be done at a quicker pace. I think the slower pace was the result of Covid-19 and its financial impact however BTD & AA that they probably will get definitely will charge ambition within this tiny company. We all will be looking for the August (360) numbers that should give us a close picture as to December (450) numbers